Source : https://pubmed.ncbi.nlm.nih.gov/41405359/
Effect of CLMs on AD is biologically plausible but clinically unproven. Signals of concern are most consistent for 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and Niemann-Pick C1-Like 1 (NPC1L1) inhibition, whereas...
Cholesterol-lowering drugs may influence atopic dermatitis via skin barrier effects, but evidence is inconclusive; statins/NPC1L1 inhibitors show concern, PCSK9 inhibitors may protect; prioritize cardiovascular benefits while monitoring dermatitis.
Most patients prescribed semaglutide lacked comprehensive pre-treatment screening, with only 1.8% fully assessed. Missing evaluations—especially for thyroid, pancreatic, and ocular risks—may increase the likelihood of severe complications despite known safety concerns.
Source : https://pubmed.ncbi.nlm.nih.gov/40431399/
Introduction: Critically ill patients in intensive care units (ICUs) are at high risk of malnutrition, which can result in muscle atrophy, polyneuropathy, increased mortality, or prolonged hospitalizations with complications and...
Review highlights importance of early, personalized ICU nutrition using enteral feeding, adequate protein, and AI/metabolomics integration to improve outcomes, reduce complications, and enable precise, multidisciplinary nutritional care.
Did you know? Childhood obesity disrupts multiple endocrine pathways, leading to insulin resistance, hormonal imbalances, and increased risk of early-onset metabolic and cardiovascular complications. These changes can also impact growth, puberty, and long-term health trajectories.
Could early endocrine-focused interventions in obesity help prevent long-term metabolic and cardiovascular disease progression?
Could early endocrine-focused interventions in obesity help prevent long-term metabolic and cardiovascular disease progression?
Source : https://pubmed.ncbi.nlm.nih.gov/40197620/
A global obesity pandemic, coupled with an increasingly ageing population, is exacerbating the burden of cardiovascular disease. Indeed, clinical and experimental evidence underscores a potential connection between obesity and ageing...
Obesity accelerates cardiovascular aging through shared mechanisms like inflammation and mitochondrial dysfunction; weight reduction and metabolic therapies may counteract these processes, reducing cardiovascular disease risk and improving longevity.